Health Care & Life Sciences » Pharmaceuticals | AcelRx Pharmaceuticals Inc.

AcelRx Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
23,426.00
33,353.00
24,399.00
43,157.00
51,508.00
47,149
Depreciation, Depletion & Amortization
593.00
866.00
1,984.00
2,052.00
1,744.00
575
Other Funds
437.00
-
215.00
205.00
204.00
15,632
Funds from Operations
3,437.00
34,318.00
15,529.00
27,124.00
33,464.00
30,942
Changes in Working Capital
2,995.00
138.00
4,424.00
2,271.00
3,699.00
1,867
Net Operating Cash Flow
442.00
34,456.00
19,953.00
29,395.00
29,765.00
29,075
Capital Expenditures
3,287.00
5,505.00
1,456.00
3,720.00
2,405.00
Purchase/Sale of Investments
3,633.00
271.00
9,659.00
5,529.00
7,565.00
Net Investing Cash Flow
6,920.00
5,776.00
8,203.00
1,809.00
9,970.00
Issuance/Reduction of Debt, Net
1,387.00
10,000.00
56,650.00
-
3,514.00
Net Financing Cash Flow
47,876.00
11,869.00
59,634.00
26.00
12,327.00
Net Change in Cash
40,514.00
28,363.00
47,884.00
27,612.00
27,408.00
Free Cash Flow
3,729.00
39,961.00
21,409.00
33,115.00
32,170.00
Change in Capital Stock
49,700.00
1,869.00
3,199.00
179.00
16,045.00

About AcelRx Pharmaceuticals

View Profile
Address
351 Galveston Drive
Redwood City California 94063
United States
Employees -
Website http://www.acelrx.com
Updated 07/08/2019
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of acute pain. Its products include DSUVIA and ZALVISO. The company was founded by Thomas A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.